

A close-up, high-contrast image of a human eye. The eye is looking towards the right. The iris area is replaced by a glowing, futuristic blue lens or implant with a circular pattern. The background is dark with some blurred blue light spots.

37th Annual JP Morgan Healthcare Conference

Todd M. Pope, President & CEO

January 7, 2019

FORWARD LOOKING STATEMENTS

This presentation includes statements relating to the Senhance™ Surgical System and our current regulatory and commercialization plans for this product. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, whether the commercialization of the Senhance Surgical System will be successful, the pace of adoption of our products by surgeons, the success and market opportunity of our products, our current cash reach, the effect on our business of existing and new regulatory requirements and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our including our Annual Report on Form 10-K filed on March 8, 2018 and other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this presentation and speak only as of the origination date of the presentation. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.



SenhanceSurgery

WHEN YOU **DIGITIZE THE**
INTERFACE BETWEEN THE
SURGEON AND THE PATIENT,
SURGERY BECOMES **SAFER**
AND MORE **PREDICTABLE**




TRANSENERIX: TRXC

FAST-GROWING, COMMERCIAL STAGE COMPANY USHERING IN A NEW ERA OF MINIMALLY INVASIVE SURGERY



SenhanceSurgery



Senhance Surgical Robotic System – the first and only **Digital Laparoscopy** platform

Significant addressable market opportunity

FDA Cleared and CE Marked

Accelerating commercial adoption

Well positioned to bring Augmented Intelligence (AI) to surgery

Strong financial position

COMPANY SNAPSHOT

FIRST NEW ENTRANT IN THE FIELD OF ABDOMINAL SURGICAL ROBOTICS IN
NEARLY 20 YEARS

**NYSE American: Listed
2014 (TRXC)**


**YoY Growth
238%**

**200+
Employees**

TIME
HEALTH CARE 50



TransEnterix Global Footprint




OUR STRATEGIC INTENT

At TransEnterix, we believe in digitizing the interface between the surgeon and patient in laparoscopy to increase control and reduce surgical variability for improved patient outcomes in today's value-based healthcare environment.

SURGICAL ROBOTICS POISED FOR GROWTH




ABDOMINAL ROBOTIC SURGERY MARKET IS PROJECTED TO GROW AT DOUBLE DIGIT CAGR OVER THE NEXT 5 YEARS



- Robotic surgery is <10% of surgery today, after nearly 20 years
- Continued expansion into additional procedures and new global markets
- Broadening solution sets enabled by new market entrants


ROBOTIC SURGERY LANDSCAPE



Historical Growth Drivers:

- Convert open surgeries to robotics
- Offset significant per-procedure cost increase with length of stay benefit vs. open surgery

DIGITAL LAPAROSCOPY OPPORTUNITY



Future Growth Drivers:

- Convert laparoscopic surgeries to robotics
- Improve laparoscopy: designed for greater precision, efficiencies, safety, ergonomics
- Provide meaningful robotic benefits to laparoscopic surgery without significant per procedure cost increase

VALUE-BASED HEALTHCARE IS FORCING HOSPITALS TO IMPROVE OUTCOMES, EFFICIENCIES, AND TALENT RETENTION

THE PRESSURE AND IMPACT ON SURGEONS ARE INCREASING UNDER THE CONSTRAINTS OF VALUE-BASED HEALTHCARE



OR
Inefficiencies




Surgical
Variability



Workforce
Challenges

Laparoscopy is the **most widely performed** surgical technique and carries limitations that **compound these factors** and can **impact clinical outcomes**

THE SENHANCE SYSTEM CAN HELP ADDRESS KEY CHALLENGES FACING HOSPITALS AND LAPAROSCOPIC SURGEONS



OR Inefficiencies

Surgical Variability

Workforce Challenges

GLOBAL CLINICAL ADOPTION UNDERWAY

BROAD APPLICABILITY, PRIMARY FOCUS IN GENERAL SURGERY, COLORECTAL AND GYNECOLOGY



SENHANCE *ULTRASONIC* HYSTERECTOMY




- 28 different procedure types performed (Colorectal, Gen Surg, GYN, URO, Thoracic)
- Set a new standard in minimally invasive robotic surgery with 3mm instruments
- First robotic system to offer security of haptic feedback
- First robotic system to offer simultaneous surgeon controlled visualization

SENHANCE DELIVERS VALUE ACROSS THE SURGICAL ENVIRONMENT

IMPROVES THE SURGICAL EXPERIENCE IN WAYS THAT MATTER


- Focused on reducing patient trauma in surgery
- Security of haptic feedback
- Minimize incisional pain

- Procedure cost comparable to laparoscopy
- Leverage current investments in laparoscopic ecosystem
- Surgeon recruiting and retention



DIGITAL LAPAROSCOPY PLATFORM – MORE THAN THE ROBOT



OUR VISION FOR DIGITAL LAPAROSCOPY GOES BEYOND THE ROBOT. WE BELIEVE DIGITIZATION IS A FOUNDATIONAL STEP FOR THE FUTURE OF SURGERY



INTEGRATING ADVANCED VISION, AUGMENTED REALITY AND AUGMENTED INTELLIGENCE INTO DIGITAL LAPAROSCOPY



DATA AND INFORMATION CAN SOON BE USED TO DERIVE VALUABLE CONTEXTUAL INSIGHTS



- Image based analytics and Augmented Intelligence (AI) will become the next wave of innovation in surgery
- Ability to combine/overlay multiple sources of information and imaging to help guide the surgical procedure
- Empowering the surgical environment with routine task automation to reduce fatigue on the surgeon and the surgical team will lead to improved outcomes and less variability in surgery
- Our technology and IP portfolio in combination with the Senhance system positions us well to be a pioneer in this space
- Insights driven surgery will help reduce surgical variability, improve patient outcomes and address workforce challenges

These Features are still in development and the safety or effectiveness of these products have not been established. This product /feature is not currently for sale.

GROWING TRANSENERIX PATENT PORTFOLIO

ESTABLISHING COMPETITIVE BARRIERS IN DIGITAL LAPAROSCOPY

Patent Applications Filed



- 133 Patents in current portfolio
- Key patent families covering
 - Haptic feedback
 - Eye tracking camera control
 - Image analytics
 - AI, AR
 - Multiport laparoscopic robotics


Total Patents in Portfolio



GROWING COMMERCIAL MOMENTUM



TOTAL REVENUE (\$M) AND SYSTEM SALES



2018 FINANCIALS (UNAUDITED)

- 2018 Revenue ~ \$24.0 million
 - 238% increase over 2017
- December 31, 2018 Balance Sheet Highlights
 - Cash & Restricted Cash ~ \$73 million
 - Debt ~ \$30 million

GLOBAL COMMERCIAL ACTIVITY

AMERICAS

- Direct sales team
- Majority of 20 largest MSAs covered
- Regulatory
 - 510(k) clearance of 3mm instrument portfolio
 - Submitted 510(k) Ultrasonic advance energy instrument
 - Submitted 510(k) Articulating instruments
- Cumulative sales 4 systems

EMEA

- Direct sales covering Germany, Italy, France & Benelux
- Distributors and agents expand coverage to other European and Middle Eastern markets
- Regulatory (CE Mark)
 - 3mm instrument portfolio
 - Ultrasonic advance energy instrument
 - Articulating instruments
- Cumulative sales 14 systems

ASIA

- Japan
 - Established local presence
 - Regulatory process underway
- Taiwan
 - Complete system and instruments regulatory approval received
 - Expect to begin Clinical program in Q1 2019
- Cumulative sales 3 systems

MILESTONES

SYSTEMATIC ACCOMPLISHMENT OF KEY GOALS PAVING THE WAY FOR CONTINUED SUCCESS

2016

- First Sale in Europe
- Established EU commercial team
- Established EU customer experience center

2017

- Senhance FDA 510(k) clearance
- US commercial team established
- Asia Pacific commercial setup
- 3mm instrument CE mark and launch
- SurgiBot China partnership
- Stryker, Novadaq, Richard-Wolf vision system compatibility

2018

- Hernia & Gall Bladder indication expansion FDA 510(k) cleared
- 3mm instrument 510(k) clearance and US launch
- Additional 5mm Instrument 510(k) clearance and US launch
- Ultrasonic Advanced Energy instrument CE mark and EU launch
- Ultrasonic Advanced Energy instrument FDA 510(k) submission
- Articulating Instrument CE mark
- Articulating Instrument FDA 510(k) submission
- First clinical case in the US and Japan
- STORZ vision system compatibility
- Taiwan regulatory clearance for Senhance
- Acquired MST assets and set up Israel R&D center
- Established Transenterix Japan



SenhanceSurgery

**WHEN YOU DIGITIZE THE
INTERFACE BETWEEN THE
SURGEON AND THE PATIENT,
SURGERY BECOMES SAFER
AND MORE PREDICTABLE**



